The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.82
Bid: 4.785
Ask: 4.845
Change: 0.09 (1.90%)
Spread: 0.06 (1.254%)
Open: 4.795
High: 4.86
Low: 4.785
Prev. Close: 4.73
SEE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Glaucoma Device Demonstrated

8 May 2007 07:02

Seeing Machines Limited08 May 2007 8 May 2007 Seeing Machines Limited ("Seeing Machines" or the "Company") SEEING MACHINES DEMONSTRATES GLAUCOMA DEVICE AT ARVO Seeing Machines (AIM: SEE), a leading developer of advanced computer basedimaging software systems, announces today that the Company is demonstrating theTrueField Analyzer(R) at the Association for Research in Vision and Ophthmalogy(ARVO) Annual Meeting in Florida from May 6-9 2007. The TrueField Analyzer(R)is the Company's revolutionary new medical device to assist doctors in detectingand managing glaucoma and other eye diseases. Seeing Machines is attending ARVO with the Company's key research partners fromthe Research School of Biological Sciences at the Australian NationalUniversity. The ARVO appearance of the TrueField Analyzer(R) is the first publicdemonstration of the device to the general Ophthmalogy community. TheOphthmalogy market will be the key market for the device when it is releasedcommercially. Nick Cerneaz, CEO of Seeing Machines, commented: "Attending this conference isvery exciting for all those who have worked on the development of TrueField andit's exciting for us to be showing the device to its intended users and gettingtheir feedback on our progress to date." Further information about the TrueField Analyzer(R) can be obtained from the website: www.truefield-analyzer.com. Further information about Seeing Machines canbe obtained from the company website www.seeingmachines.com. --- ENDS --- Enquiries:Seeing Machines Limited Insinger de Beaufort Parkgreen CommunicationsNick Cerneaz, CEO Peter Ward Victoria Thomas+61 (0) 2 6125 6501 +44 (0) 20 7190 7015 +44 (0) 20 7851 7480www.seeingmachines.com Notes to editors: About Seeing Machines Seeing Machines is an award winning Technology Company which focuses on visionbased human machine interfaces. Formed in 2000 in Canberra, Australia, SeeingMachines' purpose is to commercialise its computer-vision across a range ofindustries and applications. Seeing Machines deliver advanced computer vision solutions for researches anddevelopers in human factors, transportation safety, computer human interaction,robotics, medical research and psychology. The flagship product faceLAB(TM)provides an automated and contact-free gaze and head tracking technology, itsolves the problem of observing human behaviour naturally, non-intrusively andwith a high degree of accuracy and usability. Building on these unique facetracking and pupil measurement and monitoring capabilities, the TrueFieldAnalyzer(R) is a development undertaken by Seeing Machines in partnership withcolleagues from the Research School of Biological Sciences (RSBS) at theAustralian National University (ANU). The TrueField Analyzer(R) offers a new objective method to help doctors diagnoseand manage a range of eye diseases including glaucoma, age related maculardegeneration and diabetic retinopathy. Glaucoma affects about 2-3% of thepopulation over 40 years of age and is a leading source of blindness. Unlikemost other devices available to the clinician the TrueField Analyzer is acompletely objective test and it is quick and easy for patients and techniciansalike. The device measures both eyes concurrently and due to the reliabilitythat arises from the objective nature of the test, it has the potential tobecome a new 'gold standard' in the measurement of visual field defects and thusin the diagnosis and management of disease such as glaucoma. Seeing Machines' faceLAB(TM) product is a computer vision system that is able tomeasure the orientation and position of a human head, as well as detect blinksand estimate gaze-direction. It achieves all of this completely visually througha stereo camera system connected to advanced image processing software, with noattachments required on the subject. The product is designed to allow humanfactors researchers and designers assess the interaction of an operator in anenvironment and this finds application in designing operator environments, suchas cockpits for cars, trucks, trains, and aeroplanes for instance, and otherindustrial design applications, as well as medical and psychological researchsituations. The technology also has application in monitoring automobiledrivers and if it detects drowsiness or that the driver is distracted and theirattention has been diverted from the road, an alarm can be raised to alert thedriver to either pull over and rest in the case of drowsiness or to pay moreattention to the road. faceLAB(TM) works in real-time, enabling the behaviour of a subject to betracked. This technology is paving the way in promoting safer driving conditionsand works to enhance the driving experience and to eliminate accidents causedthrough driver drowsiness or distraction. There are many different sectors that can benefit from this revolutionarysoftware, for which it has been developed, including: automotive; academicresearch; medicine/healthcare; defence; autostereoscopy (next generationdisplays); sport; and games. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Apr 20232:45 pmRNSDirector/PDMR Shareholding
5th Apr 20239:08 amRNSPDMR Shareholding
31st Mar 202312:26 pmRNSPDMR Shareholding
29th Mar 202311:55 amRNSDirector/PDMR Shareholding
28th Mar 202311:28 amRNSPDMR Shareholding
27th Mar 202310:12 amRNSDirector/PDMR Shareholding
27th Mar 202310:07 amRNSDirector/PDMR Shareholding
24th Mar 202311:56 amRNSPDMR Shareholding
24th Mar 20238:59 amRNSDirector/PDMR Shareholding
22nd Mar 20239:16 amRNSPDMR Shareholding
17th Mar 20239:03 amRNSDirector/PDMR Shareholding
16th Mar 202311:12 amRNSDirector/PDMR Shareholding
15th Mar 20237:00 amRNSPDMR Shareholding
14th Mar 20237:00 amRNSPDMR Shareholding
13th Mar 20239:24 amRNSNo exposure to Silicon Valley Bank
9th Mar 20236:09 pmRNSDirector/PDMR Shareholding
8th Mar 20233:33 pmRNSDirector/PDMR Shareholding
8th Mar 20233:30 pmRNSDirector/PDMR Shareholding
6th Mar 20237:00 amRNSHalf year results and financial report
22nd Feb 20237:00 amRNSHalf year trading update and quarterly KPIs
15th Feb 20237:00 amRNSNotice of Results & Investor Presentation
8th Feb 20239:46 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSSeeing Machines and Mobileye to target Aftermarket
26th Jan 20239:36 amRNSDirector/PDMR Shareholding
25th Jan 202310:24 amRNSDirector/PDMR Shareholding
16th Jan 202310:28 amRNSDirector/PDMR Shareholding
13th Jan 20238:50 amRNSDirector/PDMR Shareholding
12th Jan 202310:05 amRNSDirector/PDMR Shareholding
11th Jan 202311:19 amRNSDirector/PDMR Shareholding
5th Jan 20237:00 amRNSLaunch of Silicon Platform with OMNIVISION
4th Jan 20237:00 amRNSThree Collaborations to be showcased at CES 2023
3rd Jan 20237:00 amRNSSeeing Machines to exhibit DMS & OMS at CES 2023
22nd Dec 20227:02 amRNSSeeing Machines awarded additional OEM program
7th Dec 20229:01 amRNSPDMR Shareholding
6th Dec 20228:58 amRNSPDMR Shareholding
5th Dec 20227:00 amRNSPDMR Shareholding
2nd Dec 20227:00 amRNSPDMR Shareholding
29th Nov 20223:31 pmEQSSeeing Machines CEO talks new performance indicators and focus on annual growth
29th Nov 202210:43 amRNSPDMR Shareholding
28th Nov 20228:53 amRNSResult of AGM
24th Nov 202212:43 pmRNSPDMR Shareholding
23rd Nov 20227:00 amRNSKey Performance Indicators Q1 FY 2023
21st Nov 202211:46 amRNSPDMR Shareholding
18th Nov 20227:00 amRNSPDMR Shareholding
16th Nov 20227:00 amRNSPDMR Shareholding
14th Nov 20227:00 amRNSPDMR Shareholding
11th Nov 20227:00 amRNSAppointment of Chief Financial Officer
1st Nov 202211:17 amRNSDirector/PDMR Shareholding
27th Oct 20228:18 amRNSNotice of AGM
27th Oct 20227:00 amRNSYear End Results – FY2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.